#1 of 3
71/100v3.0 six-pillar rubric
Starting at $125/mo. PeterMD is one of the providers covered in our editorial directory that dispenses or coordinates PE-22-28.
Read review →Cognitive · TREK-1 Activator
PE-22-28
PE-22-28 is a synthetic peptide derived from spadin, an endogenous TREK-1 channel inhibitor. Studied for fast-acting antidepressant effects and neuroprotection.
PE-22-28 at a glance
PE-22-28 is a synthetic peptide derived from spadin, an endogenous TREK-1 channel inhibitor. Studied for fast-acting antidepressant effects and neuroprotection. Mechanism: TREK-1 channel inhibitor. Typical route: Subcutaneous, intranasal. FDA status: Not FDA-approved. Available through specialty compounding pharmacies and peptide research suppliers. Human clinical-trial data is minimal.
Drug classTREK-1 channel inhibitor
Half-life~6 hours (estimated)
RouteSubcutaneous, intranasal
Common dosing250-500 mcg/day
FDA statusNot approved
Available throughCompounding pharmacies
Mechanism of action
PE-22-28 selectively inhibits TREK-1 potassium channels in serotonergic neurons, an action mechanistically similar to spadin. Animal models show antidepressant-like effects with onset measured in days rather than the weeks typical of SSRIs.
Dosing reference
Subcutaneous or intranasal: 250-500 mcg daily. Cycled 5 days on / 2 days off. Human dosing is not standardized.
Dosing information is provided for educational reference and is not medical advice. Patients should not initiate or modify any peptide regimen without consulting a licensed clinician. See our medical disclaimer.
FDA status & regulatory framework
Not FDA-approved. Available through specialty compounding pharmacies and peptide research suppliers. Human clinical-trial data is minimal.
U.S. telehealth providers that work with PE-22-28
#2 of 3
85/100v3.0 six-pillar rubric
Starting at $180/mo. Marek Health is one of the providers covered in our editorial directory that dispenses or coordinates PE-22-28.
Read review →#3 of 3
88/100v3.0 six-pillar rubric
Starting at $160/mo. Defy Medical is one of the providers covered in our editorial directory that dispenses or coordinates PE-22-28.
Read review →Related cognitive enhancement peptides
Frequently asked questions about PE-22-28
Can PE-22-28 treat depression?
Preclinical evidence in animal models is interesting. Human evidence is too limited to recommend PE-22-28 as a treatment for clinical depression. Patients with depression should work with a psychiatrist or licensed clinician.
Is PE-22-28 safer than SSRIs?
Safety comparison cannot be made without human trial data. SSRIs have decades of clinical experience; PE-22-28 does not.